American Thoracic Society - Sanofi Investor Call
sanofi
Dupixent® is the leader in specialty Respiratory
300
250
200
150
Leading with Pulmonologist Weekly NBRX¹
100
www
50
DUPIXENT
(dupilumab)
NUCALA
FASENRA
TEZSPIRE
XOLAIR
0
6/1/2022 7/1/2022 8/1/2022 9/1/2022 10/1/2022 11/1/2022 12/1/2022 1/1/2023 2/1/2023 3/1/2023 4/1/2023 5/1/2023
Outstanding performance
#1 Asthma NBRX
share (25%) March
20232
#1 total Asthma
patients share 41%
and new patient share
39% in Japan³
Ambition to be Best-in-
disease Type 2 Asthma
profile approved 6Y+
in U.S. & EU and 12Y+
in Japan
1. IQVIA SMART - Patients Insights Edition - weekly NBRX, data through 4/28/2023.
2. IQVIA National Source of Business monthly data with data through 3/31/2023.
3. Japan IQVIA, JMDC Database, Japan local ATU W17 Jan '23. 4. Type 2 phenotype: Eos ≥150 or FeNo > 20 ppb, and/or OCS dependence. Leading Immunology Brand in US NBRX.
45 ATS Investor CallView entire presentation